Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAC-1 and Nivolumab in Metastatic Renal Cell Carcinoma
NCT03927248Phase 2Withdrawn
- Sponsor
- HealthPartners Institute
- Start
- Sep 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of PAC-1 in renal cell carcinoma (RCC), sponsored by HealthPartners Institute. Primary endpoint: Objective Response Rate at 12 months. Planned start Sep 2020; status: withdrawn.
02
Drugs
PAC-1
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03927248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927248.